Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04256733 · ClinicalTrials.gov registry record · Early Phase 1
Cough Desensitization Therapy for Cough Hypersensitivity Syndrome
A Early Phase 1 study of Cough, sponsored by University of Montana.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04256733 is a Early Phase 1 study of Cough that has completed, run by University of Montana. The registered enrollment target is 19 participants, below the 220-participant average among 12 other Cough trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04256733, a Early Phase 1 study of Cough, has completed, sponsored by University of Montana.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate a modified behavioral treatment for chronic cough due to cough hypersensitivity syndrome (CHS). This type of CC is a non-productive cough that is due, in part, to over-expression of transient receptor potential vanilliod (TRPV) receptors in the airway epithelium, which contribute to a dry cough elicited by typically non-tussive stimuli (e.g., cold air, smells) or by low doses of tussive stimuli (e.g., smoke). Currently available treatment options are limited to neuromodulator medications (e.g., gabapentin, amytriptiline) and behavioral cough suppression therapy (BCST), neither of which is 100% effective. The primary component of BCST is teaching patients to suppress their cough in the presence of an urge-to-cough. Studies have confirmed a reduction in cough sensitivity (as tested with inhaled capsaicin) following 1-4 weeks of successful cough suppression. However, patients with severe CHS are not able to suppress their cough in the presence of uncontrollable environmental stimuli and, hence, do not respond well to the therapy. The purpose of this study is to determine the potential of treating CHS by implementing BCST while stimulating cough with progressive concentrations of inhaled diluted aerosolized capsaicin. The investigators hypothesize this treatment will result in a reduction in cough-reflex sensitivity, cough-related quality of life, and cough frequency.
Conditions Studied
Interventions
- BIOLOGICAL Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer
- BIOLOGICAL Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer
Study Locations (1)
Montana
- University of Montana - Missoula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-02-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04256733
The ClinicalTrials.gov registry entry for NCT04256733 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 12 other Cough trials with a reported enrollment target (91% lower). The listed sponsor is University of Montana, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer is the first listed.
NCT04256733 reports 1 study location spanning 1 distinct geographic area - top geographies include Montana.
Frequently Asked Questions
What is clinical trial NCT04256733 about?
NCT04256733 is a clinical study titled "Cough Desensitization Therapy for Cough Hypersensitivity Syndrome". The purpose of this study is to investigate a modified behavioral treatment for chronic cough due to cough hypersensitivity syndrome (CHS). This type of CC is a non-productive cough that is due, in part, to over-expression of transient receptor potential vanilliod (TRPV) receptors in the airway epit...
What is the current status of trial NCT04256733?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 19 participants. The study started on 2019-05-01. Estimated completion is 2021-02-13.
What conditions does trial NCT04256733 study?
This clinical trial studies the following conditions: Cough.
What interventions are being tested in trial NCT04256733?
The interventions under investigation include: Supra-threshold and progressive doses of diluted capsaicin via a Koko Digidoser nebulizer (BIOLOGICAL), Sub-threshold doses of diluted capsiacin via a KoKo Digidoser nebulizer (BIOLOGICAL).
Who is sponsoring clinical trial NCT04256733?
This trial is sponsored by University of Montana, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04256733 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.